EPISODE · May 4, 2021 · 20 MIN
Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond
from Decera Clinical Education Oncology Podcast · host Alison Birtle MD FRCP FRCR, Ignacio Durán MD PhD
In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss toxicities associated with FGFR inhibitors used in the treatment of urothelial cancer and other malignancies Presenters:Ignacio Durán, MD, PhDAssociate ProfessorGU Oncology Program LeaderDepartment of Medical OncologyHospital Universitario Marques de Valdecilla-IdivalSantander, SpainAlison Birtle, MD, FRCP, FRCRHonorary Senior LecturerFaculty of Health and MedicineUniversity of ManchesterManchester, United KingdomConsultant OncologistRosemere Cancer CentreLancashire Teaching HospitalsPreston, Lancashire, United KingdomContent based on an online IME program supported by educational grants from Janssen Pharmaceutica NV.Link to full program:http://bit.ly/3cf28jH Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
What this episode covers
Listen to Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss their thoughts on what to know about managing toxicities associated with FGFR inhibitors in the treatment of urothelial cancer and other malignancies.
NOW PLAYING
Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m